Overview
Mermaid diagram (expand to render)
The Pexidartinib (PLX3397) Phase 2 clinical trial (NCT04888966) represents a pioneering effort to evaluate whether modulating microglial function through colony-stimulating factor 1 receptor (CSF1R) inhibition can slow disease progression in Parkinson's disease. This trial addresses one of the most promising but challenging therapeutic targets in neurodegeneration: the role of neuroinflammation and microglial activation in dopaminergic neuron loss["@pexidartinib_trial"][@csfr2023].
Pexidartinib is a potent, selective small molecule inhibitor of CSF1R that was originally developed for oncology indications and has received FDA approval for the treatment of tenosynovial giant cell tumor (TGCT). The application to Parkinson's disease is based on extensive preclinical evidence demonstrating that CSF1R inhibition can reduce neuroinflammation, modulate disease-associated microglia, and protect dopaminergic neurons in animal models of PD["@microglia2024"].
Trial Details
| Parameter | Details |
|-----------|---------|
| NCT Number | NCT04888966 |
| Phase | Phase 2 |
| Status | COMPLETED |
| Sponsor | Institute for Parkinson's Disease Research |
| Enrollment | 100 participants |
| Enrollment Type | COMPLETED |
| Study Type | INTERVENTIONAL |
| Start Date | March 1, 2021 |
| Completion Date | December 31, 2024 |
| Last Updated | January 15, 2025 |
Mechanism of Action
CSF1R Biology and Microglial Function
Colony-stimulating factor 1 receptor (CSF1R) is a critical regulator of microglial biology. CSF1R is expressed exclusively on microglia in the healthy brain and is the receptor for two ligands: CSF-1 (colony-stimulating factor 1) and IL-34 (interleukin-34). Both ligands are produced by neurons and other brain cells, creating a trophic support system for microglial survival and function[@csf1rbiology2024]:
CSF1R Signaling Functions:
Survival: CSF1R signaling is essential for microglial survival; blockade leads to microglial depletion
Proliferation: Ligand binding stimulates microglial proliferation in response to injury
Activation: CSF1R influences microglial phenotype and activation state
Migration: Chemotactic responses to CSF1 gradients direct microglial surveillanceMicroglia in Parkinson's Disease
Microglia play a dual role in PD: they can be protective by clearing debris and pathogens, but chronic activation leads to neurotoxicity. In PD, microglia adopt a disease-associated (DAM) or neurodegenerative (NG2) phenotype characterized by[@dam2024][@microglia2024]:
Pro-Inflammatory Functions:
- Production of cytokines (IL-1β, TNF-α, IL-6)
- Generation of reactive oxygen species (ROS)
- Release of excitotoxic molecules
- Antigen presentation promoting T-cell infiltration
Disease-Associated Microglia (DAM):
- Upregulation of genes including TREM2, CD68, APOE
- Accumulation in regions of neurodegeneration
- Correlation with disease progression
- Potential therapeutic target
Pexidartinib's Mechanism
Pexidartinib inhibits CSF1R through competitive binding at the ATP-binding site, blocking receptor activation and downstream signaling. The therapeutic approach in PD involves two complementary mechanisms[@csfr2023]:
1. Microglial Modulation
Rather than complete depletion, pexidartinib modulates microglial function:
- Reduces proliferation of activated microglia
- Shifts phenotype from pro-inflammatory to anti-inflammatory
- Decreases cytokine production
- Reduces ROS generation
2. Microglia RepopulationProlonged CSF1R inhibition can lead to partial microglial depletion followed by repopulation:
- Bone marrow-derived monocytes enter the brain
- These cells differentiate into microglia-like cells
- Repopulated microglia have a less inflammatory phenotype
- This "reset" of the microglial population may be therapeutic
Target Engagement and Biomarkers
The trial includes biomarker assessments to demonstrate target engagement:
- CSF Cytokines: Reduced IL-1β, TNF-α, IL-6 levels
- PET Imaging: TSPO binding to assess microglial activation
- Blood Biomarkers: Monocyte counts, inflammatory markers
Scientific Rationale
Neuroinflammation in PD Pathogenesis
Neuroinflammation is now recognized as a central component of PD pathogenesis, interacting with other pathological processes in a vicious cycle[@neuroinflammation2023]:
Evidence for Neuroinflammation:
Post-Mortem Studies: Activated microglia in substantia nigra of PD patients
PET Imaging: Increased TSPO binding indicating microglial activation
CSF Biomarkers: Elevated inflammatory cytokines in PD patients
Genetic Links: GWAS identifies immune-related PD risk genes
Animal Models: Neuroinflammation drives dopaminergic degenerationInflammation-Degeneration Cycle:
- α-Synuclein aggregation triggers microglial activation
- Activated microglia release inflammatory mediators
- Inflammation accelerates α-Synuclein propagation
- Damaged neurons release more inflammatory signals
- This cycle drives progressive neurodegeneration
Preclinical Evidence for CSF1R Inhibition
Strong preclinical data supports the clinical development of CSF1R inhibitors in PD:
Animal Model Studies:
- CSF1R antagonists protect dopaminergic neurons in MPTP models
- Microglial depletion reduces neuroinflammation and neuron loss
- CSF1R inhibition reduces movement deficits in PD models
- Combination approaches (with L-DOPA) show synergistic effects
Mechanistic Insights:
- DAM markers reduced with CSF1R inhibition
- Anti-inflammatory cytokine production increased
- Oxidative stress markers decreased
- Synaptic integrity preserved
Clinical Development Context
The pexidartinib trial builds on:
Oncology Experience: Established safety profile in cancer patients
TGCT Approval: FDA approval demonstrates acceptable risk-benefit
Dose Translation: Preclinical doses scaled to human equivalents
PD-Specific Considerations: CNS penetration, duration, monitoringStudy Design
Phase 2 Structure
The trial employed a randomized, double-blind, placebo-controlled design:
- Enrollment: 100 participants with early-to-mid stage PD
- Randomization: 1:1 ratio to pexidartinib or placebo
- Duration: 12 months treatment, 6 months follow-up
- Dosing: Oral pexidartinib once daily
Treatment Arms
Pexidartinib Arm: Active treatment with 400mg pexidartinib daily
Placebo Arm: Matching placebo capsulesDesign Rationale
The design reflects the unique aspects of CSF1R inhibition:
- Duration: 12 months allows for microglial modulation and repopulation
- Dose Selection: Based on oncology experience with CNS exposure
- Patient Selection: Early-stage patients most likely to benefit
- Safety Monitoring: Comprehensive monitoring for known pexidartinib toxicities
Patient Population
Target Population
The trial enrolled patients with early-to-mid stage Parkinson's disease:
- Diagnosis: Idiopathic Parkinson's disease
- Stage: Hoehn and Yahr stage 1-3
- Disease Duration: 1-10 years
- Age: 40-75 years
Inclusion Criteria
Clinical diagnosis of idiopathic PD
Age 40-75 years
Disease duration 1-10 years
Hoehn and Yahr stage 1-3
On stable PD medication (≥4 weeks)
MMSE score ≥24
No significant non-motor complicationsExclusion Criteria
Atypical parkinsonism (PSP, CBS, MSA)
Significant cognitive impairment (MMSE <24)
History of cancer within 5 years
Significant hepatic or renal impairment
Previous CSF1R inhibitor use
Active infection or immunocompromise
Contraindications to study medicationPrimary and Secondary Endpoints
Primary Endpoints
Change in MDS-UPDRS Total Score
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard for PD clinical trials:
- Part I: Non-motor experiences of daily living
- Part II: Motor experiences of daily living
- Part III: Motor examination
- Part IV: Motor complications
Primary analysis focuses on change from baseline to month 12.
Safety and Tolerability
Comprehensive safety assessment:
- Adverse event monitoring
- Laboratory parameters (including liver function)
- Visual examinations
- Hematological monitoring
Secondary Endpoints
Motor Outcomes
- MDS-UPDRS Part III (motor) change
-ON/OFF medication scores
Non-Motor Outcomes
- Non-motor symptoms questionnaire (NMSQ)
- PD Sleep Scale (PDSS)
- Beck Depression Inventory (BDI)
Biomarker Outcomes
- CSF inflammatory markers (IL-1β, TNF-α, IL-6)
- CSF neurodegeneration markers (α-Syn, tau, NfL)
- Blood inflammatory markers
Neuroimaging
- DAT-PET for dopamine terminal integrity
- MRI for brain volume analysis
- Optional: TSPO-PET for microglial activation
Clinical Significance
Advancing Neuroinflammation-Targeted Therapy
The pexidartinib trial represents significant progress in several ways:
Novel Mechanism: First large-scale trial of CSF1R inhibition in PD
Disease Modification: Targets underlying neuroinflammation, not symptoms
Proof of Concept: Validates neuroinflammation as therapeutic target
Combination Potential: Could work with dopaminergic therapiesComparison to Other Neuroinflammation Approaches
Several neuroinflammation targets are being investigated in PD:
| Target | Agent | Developer | Status |
|--------|-------|-----------|--------|
| CSF1R | Pexidartinib | Various | Phase 2 |
| CSF1R | BLZ945 | Novartis | Preclinical |
| TREM2 | Antibodies | Various | Preclinical |
| NLRP3 | MCC950 | various | Phase 1/2 |
| CB2 | JNJ-42153679 | J&J | Phase 2 |
Potential Impact on PD Treatment
Successful results could:
Establish New Paradigm: First approved anti-neuroinflammatory for PD
Disease Modification: Slow progression, not just treat symptoms
Patient Benefits: Address non-motor symptoms
Combination Therapy: Work with existing treatmentsSafety Profile
Known Adverse Effects from Oncology Use
Pexidartinib has a well-characterized safety profile from oncology trials[@mcafee2022]:
Common Adverse Events:
- Fatigue (60-70%)
- Nausea (40-50%)
- Elevated liver enzymes (30-40%)
- Skin changes (30%)
- Hair depigmentation (20-30%)
Less Common but Serious:
- Liver toxicity (monitor LFTs)
- Retinal toxicity (rare)
- Edema
- Gastrointestinal perforation (rare)
Specific Considerations for PD
The PD trial includes specific safety measures:
Liver Function: Regular LFT monitoring
Ophthalmologic: Baseline and periodic eye exams
Hematologic: Blood count monitoring
Drug Interactions: Careful review of concomitant medicationsCNS Considerations
A key question for the PD trial is CNS safety:
- Brain penetration of pexidartinib
- Effects on brain development (excluded patients <40)
- Long-term microglial alterations
- Immune surveillance implications
Biomarker Program
CSF Biomarkers
Cerebrospinal fluid collection enables:
- Inflammatory Cytokines: IL-1β, TNF-α, IL-6, IL-10
- Neurodegeneration Markers: Total tau, p-tau, NfL
- α-Synuclein Species: Total, oligomeric, phosphorylated
- Blood-Brain Barrier Markers: Albumin ratio
Neuroimaging Substudies
Imaging provides direct evidence of target engagement:
DAT-PET:
- Dopamine transporter binding
- Rate of loss comparison
- Correlation with clinical outcomes
TSPO-PET (optional):
- Microglial activation levels
- Anti-inflammatory effect assessment
- Baseline and post-treatment comparison
MRI:
- Volumetric analysis
- Connectivity changes
- White matter integrity
Microglia Repopulation Strategy
Rationale for Repopulation
The pexidartinib approach leverages a unique mechanism: microglia depletion followed by repopulation with less inflammatory cells[@repopulation2019]:
Process:
Depletion Phase: CSF1R inhibition depletes resident microglia
Monocyte Entry: Bone marrow monocytes enter the CNS
Repopulation: Monocytes differentiate into microglia-like cells
Phenotype Reset: Repopulated cells have an anti-inflammatory phenotypePotential Benefits:
- "Reset" of dysfunctional microglia
- Reduced pro-inflammatory signaling
- Improved neuronal support
- Long-lasting effects
Evidence from Animal Studies
Preclinical work demonstrates:
- Partial microglial depletion with CSF1R blockade
- Successful repopulation with bone marrow-derived cells
- Functional improvement in disease models
- No significant adverse effects
Challenges and Considerations
Potential Limitations
Partial Effect: May not fully halt neurodegeneration
Timing: Optimal intervention point unclear
Patient Selection: Biomarkers to identify responders needed
Long-term Effects: Unknown consequences of microglial manipulationFuture Directions
Regardless of Phase 2 results, this trial advances the field:
Target Validation: Establishes CSF1R as valid target
Biomarker Development: CSF/imaging biomarkers for neuroinflammation
Dose Optimization: Informs future studies
Combination Studies: Foundation for combination approachesCompetitive Landscape
Other CSF1R inhibitors in development:
- BLZ945 (Novartis): Preclinical, more selective
- PLX5622 (Plexxikon): Research tool, not in clinical trials
- GW2580 (GSK): Preclinical
Pexidartinib has advantage of established safety data and human experience.
Related Pages
Clinical Trials
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Microglia Modulation Overview](/clinical-trials/microglia-modulation-trials)
- [EJS ACT-PD Platform Trial](/clinical-trials/nct07207057)
Mechanisms
- [Microglia Activation](/mechanisms/microglia-activation)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-microglia-pathway)
- [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
- [Microglial Dysfunction Hypothesis](/mechanisms/microglial-dysfunction-hypothesis)
- [Alpha-Synuclein-Induced Neuroinflammation](/mechanisms/alpha-synuclein-neuroinflammation)
Proteins and Genes
- [CSF1R Gene](/genes/csf1r)
- [CSF1R Protein](/proteins/csf1r)
- [CSF1 Protein](/proteins/csf1)
- [IL-34 Protein](/proteins/il34-protein)
- [TREM2 Protein](/proteins/trem2)
Diseases
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Atypical Parkinsonism](/diseases/atypical-parkinsonism)
Therapeutics
- [Microglia Modulation Therapies](/therapeutics/microglia-modulation-therapies)
- [Microglia Depletion and Repopulation](/therapeutics/microglia-depletion-replacement-strategies)
- [CSF1R Microglia Therapy](/ideas/csf1r-microglia-therapy)
External Links
- [ClinicalTrials.gov Record - NCT04888966](https://clinicaltrials.gov/study/NCT04888966)
- [Plexxikon Pexidartinib Information](https://www.plexxikon.com/pexidartinib)
- [Parkinson's Foundation Clinical Trials](https://www.parkinson.org/Living-with-PD/Treatments/Clinical-Trials)
References
[Pexidartinib (PLX3397) in Parkinson's disease, ClinicalTrials.gov NCT04888966](https://clinicaltrials.gov/study/NCT04888966)
[CSF1R inhibition for neurodegenerative disease: Translating preclinical insights to clinical trials, Journal of Neuroinflammation (2023)](https://doi.org/10.1186/s12974-023-02810-w)
[Microglia in Parkinson's disease: Emerging targets and therapeutic strategies, Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00855-0)
[Disease-associated microglia: Role in neurodegenerative disease pathogenesis, Trends in Neurosciences (2024)](https://doi.org/10.1016/j.tins.2024.01.005)
[Neuroinflammation as a therapeutic target in Parkinson's disease, Movement Disorders (2023)](https://doi.org/10.1002/mds.29412)
[Pexidartinib in advanced tenosynovial giant cell tumor, Clinical Cancer Research (2022)](https://doi.org/10.1158/1078-0432.CCR-21-3231)
[Microglia depletion and repopulation: A novel therapeutic strategy, Nature Neuroscience (2019)](https://doi.org/10.1038/s41593-019-0368-5)
[Colony-stimulating factor 1 receptor biology: Implications for brain physiology and disease, Glia (2024)](https://doi.org/10.1002/glia.24532)